AbbVievs.Bristol Myers Squibb
ABBV vs BMY · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 3.4× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (14.2 vs 70.2); year to date, Bristol Myers Squibb leads (+24.7% vs +15.8%).
Side by side
| ABBV | BMY | |
|---|---|---|
| Market cap | $443B | $132B |
| Price | $265.79 | $67.92 |
| Today | +0.5% | +1.0% |
| Return YTD | +15.8% | +24.7% |
| Return 1Y | +25.6% | +40.4% |
| P/E | 70.2 | 14.2 |
| P/S | 6.9 | 2.7 |
| P/B | 312.1 | 5.9 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →More ABBV & BMY comparisons
Other head-to-heads in the Big pharma segment.
See where ABBV and BMY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →